Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586999 · ClinicalTrials.gov registry record · Phase 1
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03586999: Completed Phase 1 study, sponsored by University of Colorado, Denver.
NCT03586999 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03586999, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
Primary Outcome
Efficacy will be measured according to 2017 RECIL criteria. Responses will be assessed by the investigator and will be based on PET/CT scan to be obtained after 6 cycles of induction chemotherapy.
Interventions
- DRUG Cyclophosphamide
- DRUG Nivolumab
- DRUG Etoposide
- DRUG Prednisolone
- DRUG Oncovin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
What the finished NCT03586999 record still lists
NCT03586999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03586999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03586999 about?
NCT03586999 is a clinical study titled "Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas". This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
What is the current status of trial NCT03586999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-11-07. Estimated completion is 2022-09-20.
What interventions are being tested in trial NCT03586999?
The interventions under investigation include: Cyclophosphamide (DRUG), Nivolumab (DRUG), Etoposide (DRUG), Prednisolone (DRUG), Oncovin (DRUG).
Who is sponsoring clinical trial NCT03586999?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03586999's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI